RNAi leaders Isis, Alnylam form new company
Isis Pharmaceuticals and Alnylam Pharmaceuticals--two leaders in the hot field of RNA--have teamed up to form Regulus Therapeutics, a company that will focus on developing new drugs based on micro-RNA. Micro-RNA is one of two types of RNA interference found in all human cells and affects how genes are turned off and on. MiRNAs regulate whole networks of genes; therefore therapeutics based on this technology represent a new approach to target the pathways of disease, according to the companies.
Both companies will grant Regulus licenses to their IP for miRNA therapeutic applications, as well as certain early fundamental patents in the miRNA field. Alnylam will make an initial investment of $10 million to balance venture ownership; thereafter Isis and Alnylam will share funding of Regulus. Regulus will be operated as an independent company with an independent Board of Directors and management team, which will include Nobel laureate David Baltimore.
"The emerging biology of microRNAs points to a completely new understanding of cellular mechanisms for regulation of gene expression," noted Baltimore. "I believe that microRNAs represent previously unexplored disease targets where pharmacological approaches could lead to the emergence of novel therapies for many human disorders. "
- see this release for more
Related Articles:
A billion-dollar lesson in RNAi economics. Report
Isis gains from big RNAi deal. Report
Roche harnesses Alnylam's RNAi tech in $1B deal. Report
Comments (2) | Post a comment
More stories about RNAi Alnylam genes Regulus Therapeutics microRNA David Baltimore Isis Pharmaceuticals New Drugs
Comments
By Jon | Posted 4:33pm | September 7, 2007
In my opinion, it is not a coincidence that the two leading pioneers in the field went into a joint venture. A lot of this deal probably came down to one man, Dr. Monaharan. Before he became an exec at Alnylam he was an exec at Isis for 12 years. See http://www.newsvisual.com/newsvisual/2007/09/9-7-07-alnylam-.html
By Anonymous | Posted 9:50pm | September 26, 2008
Dr.Xanthopoulos is probably a very good executive but I would not like to have him as CEO in my company in light of his not so very public history from Rockefeller, Karolinska Institute and Aurora...
But again, I'm sure he's good but I like him to be as far from me and any of my companies as possible.
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
